Amarin (AMRN) Competitors $10.99 +0.01 (+0.09%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$10.75 -0.24 (-2.18%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. ARDX, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, PRAX, and NRIXShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Ardelyx Zymeworks LENZ Therapeutics CureVac CorMedix Chimerix Avid Bioservices Cronos Group Praxis Precision Medicines Nurix Therapeutics Amarin (NASDAQ:AMRN) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Does the media prefer AMRN or ARDX? In the previous week, Ardelyx had 17 more articles in the media than Amarin. MarketBeat recorded 18 mentions for Ardelyx and 1 mentions for Amarin. Ardelyx's average media sentiment score of 0.90 beat Amarin's score of 0.75 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer AMRN or ARDX? Amarin received 305 more outperform votes than Ardelyx when rated by MarketBeat users. Likewise, 73.20% of users gave Amarin an outperform vote while only 67.46% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84473.20% Underperform Votes30926.80% ArdelyxOutperform Votes53967.46% Underperform Votes26032.54% Which has more volatility & risk, AMRN or ARDX? Amarin has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Which has better earnings & valuation, AMRN or ARDX? Ardelyx has higher revenue and earnings than Amarin. Ardelyx is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$214.11M1.06-$59.11M-$3.64-3.02Ardelyx$361.71M2.62-$39.14M-$0.22-18.00 Do institutionals and insiders hold more shares of AMRN or ARDX? 22.3% of Amarin shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 3.3% of Amarin shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is AMRN or ARDX more profitable? Ardelyx has a net margin of -11.73% compared to Amarin's net margin of -16.33%. Amarin's return on equity of -7.22% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Ardelyx -11.73%-24.87%-10.51% Do analysts prefer AMRN or ARDX? Amarin presently has a consensus price target of $7.00, suggesting a potential downside of 36.31%. Ardelyx has a consensus price target of $10.39, suggesting a potential upside of 162.35%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Ardelyx 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 SummaryArdelyx beats Amarin on 15 of the 19 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.59M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-122.119.0626.7919.70Price / Sales1.06259.83393.69121.79Price / CashN/A65.8538.2534.62Price / Book8.146.456.774.50Net Income-$59.11M$143.98M$3.23B$248.22M7 Day Performance3.88%0.38%0.42%-0.80%1 Month Performance6.08%2.14%9.06%11.52%1 Year Performance-34.92%-0.33%18.55%8.99% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.3588 of 5 stars$10.99+0.1%$7.00-36.3%-37.0%$227.59M$214.11M-122.11360ARDXArdelyx4.4936 of 5 stars$3.53-2.5%$10.39+194.3%-49.4%$844.57M$361.71M-22.0690Insider TradeGap DownZYMEZymeworks3.3609 of 5 stars$12.02+6.3%$21.00+74.7%+27.3%$836.32M$76.30M-8.01460News CoveragePositive NewsAnalyst ForecastAnalyst RevisionLENZLENZ Therapeutics1.9263 of 5 stars$29.37+11.5%$46.60+58.7%+53.3%$826.65MN/A-16.59110Gap UpCVACCureVac3.5763 of 5 stars$3.62+4.3%$14.00+286.7%+6.4%$812.10M$535.18M6.58880News CoverageEarnings ReportCRMDCorMedix2.0819 of 5 stars$11.86+1.7%$15.00+26.5%+135.3%$804.40M$82.55M-14.6430CMRXChimerix0.5666 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990CDMOAvid Bioservices0.8011 of 5 stars$12.50+0.1%$12.25-2.0%+37.5%$799.18M$139.91M-5.23320High Trading VolumeCRONCronos Group1.0011 of 5 stars$2.05+3.5%$3.50+70.7%-26.5%$790.08M$117.62M-15.77450Positive NewsHigh Trading VolumePRAXPraxis Precision Medicines3.1548 of 5 stars$38.42+0.2%$116.50+203.2%-10.0%$782.58M$8.12M-3.73110Positive NewsNRIXNurix Therapeutics2.3926 of 5 stars$10.18+7.2%$30.44+199.1%-38.0%$776.08M$56.42M-3.52300Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Ardelyx Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives CureVac Alternatives CorMedix Alternatives Chimerix Alternatives Avid Bioservices Alternatives Cronos Group Alternatives Praxis Precision Medicines Alternatives Nurix Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.